Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. | JAMA Netw Open | 2022 | 36136330 | PubTator, text mining | PubMed |
| Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. | Curr Oncol | 2022 | 36135052 | PubTator, text mining | PubMed |
| Biclonal Desmoid-Type Fibromatosis With Two Beta-Catenin Mutations: Evidence for the Recruitment of Normal Myofibroblasts. | Cureus | 2022 | 36134040 | PubTator, text mining | PubMed |
| What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer? | Front Oncol | 2022 | 36132150 | PubTator, text mining | PubMed |
| Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. | Oncologist | 2022 | 36124924 | PubTator, text mining | PubMed |
| Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients. | Front Oncol | 2022 | 36119527 | PubTator, text mining | PubMed |
| Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing. | Cancer Genet | 2022 | 36116289 | PubTator, text mining | PubMed |
| DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. | Front Oncol | 2022 | 36110934 | PubTator, text mining | PubMed |
| Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial. | JCO Precis Oncol | 2022 | 36103643 | PubTator, text mining | PubMed |
| Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants. | Proc Natl Acad Sci U S A | 2022 | 36099300 | PubTator, text mining | PubMed |
| PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies. | Front Pharmacol | 2022 | 36091750 | PubTator, text mining | PubMed |
| Fanconi anemia and dyskeratosis congenita/telomere biology disorders: Two inherited bone marrow failure syndromes with genomic instability. | Front Oncol | 2022 | 36091172 | PubTator, text mining | PubMed |
| Eligibility, uptake and response to germline genetic testing in women with DCIS. | Front Oncol | 2022 | 36091166 | PubTator, text mining | PubMed |
| Progress in surgical oncology: Gynecology perspective. | J Surg Oncol | 2022 | 36087083 | PubTator, text mining | PubMed |
| Tumor purity adjusted beta values improve biological interpretability of high-dimensional DNA methylation data. | PLoS One | 2022 | 36084090 | PubTator, text mining | PubMed |
| A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer. | Front Immunol | 2022 | 36081518 | PubTator, text mining | PubMed |
| DNA Methylation in Offspring Conceived after Assisted Reproductive Techniques: A Systematic Review and Meta-Analysis. | J Clin Med | 2022 | 36078985 | PubTator, text mining | PubMed |
| PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. | Cancers (Basel) | 2022 | 36077867 | PubTator, text mining | PubMed |
| Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives. | Cancers (Basel) | 2022 | 36077752 | PubTator, text mining | PubMed |
| Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology. | Cancers (Basel) | 2022 | 36077694 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=45